Combination cancer therapy with bis(thiohydrazide) amide compounds

ABSTRACT

Disclosed is a method of treating a subject with cancer, the method comprising the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/m 2  to 315 μmol/m 2 ; and a bis(thiohydrazide amide) compound in an amount between about 1473 μmol/m 2  and about 1722 μmol/m 2 .

RELATED APPLICATION

This application is a continuation of the U.S. application Ser. No.11/918,357, filed on Aug. 25, 2008, issuing, which is a U.S. NationalStage of International Application No. PCT/US/2006/014531, filed Apr.13, 2006, which claims the benefit of U.S. Provisional Application No.60/672,139, filed on Apr. 15, 2005. The entire teachings of the aboveapplications are incorporated herein by reference.

BACKGROUND OF THE INVENTION

The taxanes are an important class of anticancer agents. In particular,Taxol™ (paclitaxel) is an effective anticancer agent, especially in thetreatment of ovarian cancer, metastatic breast cancer, non-small celllung cancer (NSCLC) and AIDS-related Kaposi's sarcoma. However, there isstill a significant need in the art for improvement in the efficacy ofpaclitaxel therapy, both in terms of the proportion of patients whorespond to therapy and the survival benefit imparted. Moreover,administration of Taxol has side effects, including reducing immunefunction by reducing natural killer (NK) cell activity.

In an attempt to improve efficacy, paclitaxel is sometimes used incombination with other anticancer agents. For example, carboplatin inthe treatment of NSCLC. Such combinations can have an additive benefitor increased response rate, but can tend to also combine the side effectprofiles of each agent. Other agents have been researched, for example,bis(thiohydrazide amides) have been tested in animal models as describedin U.S. Pat. Nos. 6,800,660, 6,762,204, U.S. patent application Ser.Nos. 10/345,885 filed Jan. 15, 2003, and 10/758,589, Jan. 15, 2004, theentire teachings of which are incorporated herein by reference.

However, there is still an urgent need for particular combinationtherapies that can enhance the antitumor effects of paclitaxel withoutfurther increasing side effects suffered by patients.

SUMMARY OF THE INVENTION

It is now found that certain bis(thiohydrazide) amide and taxanecombinations are surprisingly effective at treating subjects with cancerwithout further increasing side effects. The particular combinationtherapies disclosed herein demonstrate surprising biological activity byraising Hsp70 levels (see Example 3), by demonstrating significantanticancer effects (see Examples 4-5), and by halting or reversing sideeffects (see Examples 4-5) such as the reduction in natural killer (NK)cell activity typically associated with Taxol™ administration.

A method of treating a subject with cancer includes the step ofco-administering to the subject over three to five weeks, a taxane in anamount of between about 243 μmol/m2 to 315 μmol/m2 (e.g., equivalent topaclitaxel in about 210-270 mg/m2); and a bis(thiohydrazide amide) in anamount between about 1473 μmol/m2 and about 1722 μmol/m2 (e.g., Compound(1) in about 590-690 mg/m2). The bis(thiohydrazide amide) is representedby Structural Formula I:

Y is a covalent bond or an optionally substituted straight chainedhydrocarbyl group, or, Y, taken together with both >C═Z groups to whichit is bonded, is an optionally substituted aromatic group.

R₁-R₄ are independently —H, an optionally substituted aliphatic group,an optionally substituted aryl group, or R₁ and R₃ taken together withthe carbon and nitrogen atoms to which they are bonded, and/or R₂ and R₄taken together with the carbon and nitrogen atoms to which they arebonded, form a non-aromatic heterocyclic ring optionally fused to anaromatic ring.

R₇-R₈ are independently —H, an optionally substituted aliphatic group,or an optionally substituted aryl group.

Z is O or S.

In various embodiments, a method of treating a subject with cancerincludes administering to the subject effective amounts of each of aplatinum anticancer compound; a taxane or a pharmaceutically acceptablesalt or solvate thereof; and a bis(thiohydrazide amide) represented byStructural Formula I or a pharmaceutically acceptable salt or solvatethereof.

In various embodiments, a method of treating a subject with cancerincludes administering to the subject once every three weeks,independently or together a taxane in an amount of about 205 μmol/m2(e.g., paclitaxel in about 175 mg/m2); and a bis(thiohydrazide amide)represented by Structural Formula I or a pharmaceutically acceptablesalt or solvate thereof in an amount between about 220 μmol/m2 and about1310 μmol/m2 (e.g., Compound (1) in about 88-525 mg/m2).

In various embodiments, a pharmaceutical composition includes apharmaceutically acceptable carrier or diluent. In some embodiments, themolar ratio of bis(thiohydrazide amide) to taxane can be between about5.5:1 and about 5.9:1, in certain embodiments, between about 2.7:1 andabout 2.9:1, and in particular embodiments, between about 4.1:1 andabout 4.5:1.

In various embodiments, the invention includes the use of abis(thiohydrazide amide) for the manufacture of medicament for treatingcancer in combination with a taxane in each of the molar ratiosdescribed above. In some embodiments, the invention includes the use ofa bis(thiohydrazide amide) and taxane for the manufacture of medicamentfor treating cancer in each of the molar ratios described above.

The taxanes employed in the invention, e.g., paclitaxel, are describedin the Detailed Description section below.

In various embodiments, a pharmaceutically acceptable salt or solvate ofeither the bis(thiohydrazide)amide or taxane anticancer agents can beemployed, optionally with a pharmaceutically acceptable carrier ordiluent. In certain embodiments, a pharmaceutical composition includesthe bis(thiohydrazide) amide, the taxane, and a pharmaceuticallyacceptable carrier or diluent.

The methods are particularly effective for treating the claimed cancersas demonstrated in the Examples, and halting or reversing side effectssuch as the reduction in natural killer (NK) cell activity typicallyassociated with Taxol™ administration.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A, 1B, and 1C are bar graphs showing the percent increase inHsp70 plasma levels associated with administration of the Compound(1)/paclitaxel combination therapy at 1 hour (FIG. 1A), 5 hours (FIG.1B), and 8 hours (FIG. 1C) after administration.

DETAILED DESCRIPTION OF THE INVENTION

A description of preferred embodiments of the invention follows.

In various embodiments, a method of treating a subject with cancerincludes the step of co-administering to the subject over three to fiveweeks, a taxane in an amount of between about 243 μmol/m2 to 315 μmol/m2(e.g., equivalent to paclitaxel in about 210-270 mg/m2); and abis(thiohydrazide amide) (e.g., as represented by Structural Formula I)in an amount between about 1473 μmol/m2 and about 1722 μmol/m2 (e.g.,Compound (1) in about 590-690 mg/m2).

A subject, e.g., typically a human subject, can be treated for anycancer described herein. Typically, the cancer can be a soft tissuesarcoma (e.g., typically soft tissue sarcomas other than GIST) ormetastatic melanoma. In some embodiments, the cancer is metastaticmelanoma.

In some embodiments, the taxane and the bis(thio-hydrazide) amide caneach be administered in three equal weekly doses for three weeks of afour week period. In preferred embodiments, the four week administrationperiod can be repeated until the cancer is in remission.

The taxane can be any taxane defined herein. In particular embodiments,the taxane is paclitaxel intravenously administered in a weekly dose ofabout 94 μmol/m2 (80 mg/m2).

In various embodiments, the bis(thiohydrazide amide) can beintravenously administered in a weekly dose of between about 500 μmol/m2and about 562 μmol/m2, or more typically in a weekly dose of about 532μmol/m2. (e.g., Compound (1) in about 590-690 mg/m2).

In some embodiments, the subject is treated for metastatic melanoma. Incertain embodiments, the subject is treated for soft tissue sarcomasother than GIST.

In preferred embodiments, a method of treating a human subject withcancer includes intravenously administering to the subject in a fourweek period, three equal weekly doses of paclitaxel in an amount ofabout 94 μmol/m2; and a bis(thiohydrazide amide) represented by thefollowing Structural Formula:

or a pharmaceutically acceptable salt or solvate thereof in an amount ofabout 532 μmol/m2. Typically, the cancer is a soft tissue sarcomas(e.g., typically soft tissue sarcomas other than GIST) or metastaticmelanoma.

In various embodiments, the subject can be intravenously administeredbetween about 220 μmol/m2 and about 1310 μmol/m2 (e.g., Compound (1) inabout 88-525 mg/m2) of the bis(thiohydrazide amide) once every 3 weeks,generally between about 220 μmol/m2 and about 1093 μmol/m2 (e.g.,Compound (1) in about 88-438 mg/m2) once every 3 weeks, typicallybetween about 624 μmol/m2 and about 1124 μmol/m2 m2 (e.g., Compound (1)in about 250-450 mg/m2), more typically between about 811 μmol/m2 andabout 936 μmol/m2 m2 (e.g., Compound (1) in about 325-375 mg/m2), or inparticular embodiments, about 874 μmol/m2 ((e.g., Compound (1) in about350 mg/m2). In particular embodiments, the subject can be intravenouslyadministered between about 582 μmol/m2 and about 664 μmol/m2 (e.g.,Compound (1) in about 233-266 mg/m2) of the bis(thiohydrazide amide)once every 3 weeks. In certain embodiments, the bis(thiohydrazide amide)is in an amount of about 664 μmol/m2 (e.g., Compound (1) in about 266mg/m2).

In various embodiments, the subject can be intravenously administeredbetween about 200 μmol/m2 to about 263 μmol/m2 of the taxane aspaclitaxel once every 3 weeks (e.g., paclitaxel in about 175-225 mg/m2).In some embodiments, the subject can be intravenously administeredbetween about 200 μmol/m2 to about 234 μmol/m2 of the taxane aspaclitaxel once every 3 weeks (e.g., paclitaxel in about 175-200 mg/m2).In certain embodiments, the paclitaxel is administered in an amount ofabout 234 μmol/m2 (200 mg/m2). In certain embodiments, the paclitaxel isadministered in an amount of about 205 μmol/m2 (175 mg/m2)

In various embodiments, the taxane, e.g., paclitaxel, and thebis(thiohydrazide amide), e.g., Compound (1), can be administeredtogether in a single pharmaceutical composition.

In various embodiments, a method of treating a subject with cancerincludes administering to the subject once every three weeks,independently or together a taxane in an amount of about 205 μmol/m2(e.g., paclitaxel in about 175 mg/m2); and a bis(thiohydrazide amide)represented by Structural Formula I or a pharmaceutically acceptablesalt or solvate thereof in an amount between about 220 μmol/m2 and about1310 μmol/m2 (e.g., Compound (1) in about 88-525 mg/m2). Typically, thetaxane is paclitaxel intravenously administered in an amount of about205 μmol/m2. The bis(thiohydrazide amide) can typically be intravenouslyadministered between about 220 μmol/m2 and about 1093 μmol/m2 (e.g.,Compound (1) in about 88-438 mg/m2), more typically between about 749μmol/m2 and about 999 μmol/m2 (e.g., compound (1) in about 300-400mg/m2), in some embodiments between about 811 μmol/m2 and about 936μmol/m2 (e.g., Compound (1) in about 325-375 mg/m2). In certainembodiments, the bis(thiohydrazide amide) can be Compound (1)intravenously administered between about 874 μmol/m2 (about 350 mg/m2).

In a particular embodiment, a method of treating a subject with cancerincludes intravenously administering to the subject in a single dose perthree week period: paclitaxel in an amount of about 205 μmol/m2 (175mg/m2); and Compound (1) or a pharmaceutically acceptable salt orsolvate thereof in an amount of about 874 μmol/m2 (350 mg/m2), whereinthe cancer is a soft tissue sarcomas other than GIST or metastaticmelanoma.

In various embodiments, a pharmaceutical composition includes apharmaceutically acceptable carrier or diluent; and a molar ratio of abis(thiohydrazide amide) to a taxane between about 5.5:1 and about5.9:1, wherein the bis(thiohydrazide amide) represented by StructuralFormula I or a pharmaceutically acceptable salt or solvate thereof. Insome embodiments, the molar ratio of the bis(thiohydrazide amide) to thetaxane is between about 5.6:1 and about 5.8:1, or more typically, about5.7:1. In certain embodiments, the taxane is paclitaxel or apharmaceutically acceptable salt or solvate thereof. In particularembodiments, the bis(thiohydrazide amide) is Compound (1).

In various embodiments, a pharmaceutical composition includes apharmaceutically acceptable carrier or diluent; and a molar ratio of abis(thiohydrazide amide) to a taxane between about 2.6:1 and about3.0:1, wherein the bis(thiohydrazide amide) represented by StructuralFormula I or a pharmaceutically acceptable salt or solvate thereof. Insome embodiments, the molar ratio of the bis(thiohydrazide amide) to thetaxane is between about 2.7:1 and about 2.9:1, or more typically, about2.8:1. In certain embodiments, the taxane is paclitaxel or apharmaceutically acceptable salt or solvate thereof. In particularembodiments, the bis(thiohydrazide amide) is Compound (1).

In various embodiments, a pharmaceutical composition includes apharmaceutically acceptable carrier or diluent; and a molar ratio of abis(thiohydrazide amide) to a taxane between about 4.1:1 and about4.5:1, wherein the bis(thiohydrazide amide) represented by StructuralFormula I or a pharmaceutically acceptable salt or solvate thereof. Insome embodiments, the molar ratio of the bis(thiohydrazide amide) to thetaxane is between about 4.2:1 and about 4.4:1, or more typically, about4.3:1. In certain embodiments, the taxane is paclitaxel or apharmaceutically acceptable salt or solvate thereof. In particularembodiments, the bis(thiohydrazide amide) is Compound (1).

In various embodiments, the invention includes the use of abis(thiohydrazide amide) for the manufacture of medicament for treatingcancer in combination with a taxane in a molar ratio ofbis(thiohydrazide amide) to taxane between about 5.5:1 and about 5.9:1,typically between about 5.6:1 and about 5.8:1, more typically about5.7:1, wherein the bis(thiohydrazide amide) is represented by StructuralFormula I. In some embodiments, the molar ratio of bis(thiohydrazideamide) to taxane can be between about 2.6:1 and about 3.0:1, typicallybetween about 2.7:1 and about 2.9:1, more typically about 2.8:1. In someembodiments, the molar ratio of bis(thiohydrazide amide) to taxane canbe between about 4.1:1 and about 4.5:1, typically between about 4.2:1and about 4.4:1, more typically about 4.3:1.

In various embodiments, the invention includes the use of abis(thiohydrazide amide) and taxane for the manufacture of medicamentfor treating cancer in a molar ratio of bis(thiohydrazide amide) totaxane between about 5.5:1 and about 5.9:1, typically between about5.6:1 and about 5.8:1, more typically about 5.7:1, wherein thebis(thiohydrazide amide) is represented by Structural Formula I. In someembodiments, the molar ratio of bis(thiohydrazide amide) to taxane canbe between about 2.6:1 and about 3.0:1, typically between about 2.7:1and about 2.9:1, more typically about 2.8:1. In some embodiments, themolar ratio of bis(thiohydrazide amide) to taxane can be between about4.1:1 and about 4.5:1, typically between about 4.2:1 and about 4.4:1,more typically about 4.3:1.

The bis(thiohydrazide amides) employed in the disclosed invention arerepresented by Structural Formula I, or a pharmaceutically acceptablesalt or solvate thereof.

In one embodiment, Y in Structural Formula I is a covalent bond,—C(R₅R₆)—, —(CH₂CH₂)—, trans-(CH═CH)—, cis-(CH═CH)— or —(C≡C)— group,preferably —C(R₅R₆)—. R₁-R₄ are as described above for StructuralFormula I. R₅ and R₆ are each independently —H, an aliphatic orsubstituted aliphatic group, or R₅ is —H and R₆ is an optionallysubstituted aryl group, or, R₅ and R₆, taken together, are an optionallysubstituted C2-C6 alkylene group. The pharmaceutically acceptable cationis as described in detail below.

In specific embodiments, Y taken together with both >C═Z groups to whichit is bonded, is an optionally substituted aromatic group. In thisinstance, certain bis(thiohydrazide amides) are represented byStructural Formula II:

wherein Ring A is substituted or unsubstituted and V is —CH— or —N—. Theother variables in Structural Formula II are as described herein forStructural Formula I or III.

In particular embodiments, the bis(thiohydrazide amides) are representedby Structural Formula III:

R₁-R₈ and the pharmaceutically acceptable cation are as described abovefor Structural Formula I.

In Structural Formulas I-III, R₁ and R₂ are the same or different and/orR₃ and R₄ are the same or different; preferably, R₁ and R₂ are the sameand R₃ and R₄ are the same. In Structural Formulas I and III, Z ispreferably O. Typically in Structural Formulas I and III, Z is O; R₁ andR₂ are the same; and R₃ and R₄ are the same. More preferably, Z is O; R₁and R₂ are the same; R₃ and R₄ are the same, and R₇ and R₈ are the same.

In other embodiments, the bis(thiohydrazide amides) are represented byStructural Formula III: R₁ and R₂ are each an optionally substitutedaryl group, preferably an optionally substituted phenyl group; R₃ and R₄are each an optionally substituted aliphatic group, preferably an alkylgroup, more preferably, methyl or ethyl; and R₅ and R₆ are as describedabove, but R₅ is preferably —H and R₆ is preferably —H, an aliphatic orsubstituted aliphatic group.

Alternatively, R₁ and R₂ are each an optionally substituted aryl group;R₃ and R₄ are each an optionally substituted aliphatic group; R₅ is —H;and R₆ is —H, an aliphatic or substituted aliphatic group. Preferably,R₁ and R₂ are each an optionally substituted aryl group; R₃ and R₄ areeach an alkyl group; and R₅ is —H and R₆ is —H or methyl. Even morepreferably, R₁ and R₂ are each an optionally substituted phenyl group;R₃ and R₄ are each methyl or ethyl; and R₅ is —H and R₆ is —H or methyl.Suitable substituents for an aryl group represented by R₁ and R₂ and analiphatic group represented by R₃, R₄ and R₆ are as described below foraryl and aliphatic groups.

In another embodiment, the bis(thiohydrazide amides) are represented byStructural Formula III: R₁ and R₂ are each an optionally substitutedaliphatic group, preferably a C3-C8 cycloalkyl group optionallysubstituted with at least one alkyl group, more preferably cyclopropylor 1-methylcyclopropyl; R₃ and R₄ are as described above for StructuralFormula I, preferably both an optionally substituted alkyl group; and R₅and R₆ are as described above, but R₅ is preferably —H and R₆ ispreferably —H, an aliphatic or substituted aliphatic group, morepreferably —H or methyl.

Alternatively, the bis(thiohydrazide amides) are represented byStructural Formula III: R₁ and R₂ are each an optionally substitutedaliphatic group; R₃ and R₄ are as described above for Structural FormulaI, preferably both an optionally substituted alkyl group; and R₅ is —Hand R₆ is —H or an optionally substituted aliphatic group. Preferably,R₁ and R₂ are both a C3-C8 cycloalkyl group optionally substituted withat least one alkyl group; R₃ and R₄ are both as described above forStructural Formula I, preferably an alkyl group; and R₅ is —H and R₆ is—H or an aliphatic or substituted aliphatic group. More preferably, R₁and R₂ are both a C3-C8 cycloalkyl group optionally substituted with atleast one alkyl group; R₃ and R₄ are both an alkyl group; and R₅ is —Hand R₆ is —H or methyl. Even more preferably, R₁ and R₂ are bothcyclopropyl or 1-methylcyclopropyl; R₃ and R₄ are both an alkyl group,preferably methyl or ethyl; and R₅ is —H and R₆ is —H or methyl.

In specific embodiments, the bis(thiohydrazide amides) are representedby Structural Formula IV:

wherein: R₁ and R₂ are both phenyl, R₃ and R₄ are both methyl, and R₅and R₆ are both —H; R₁ and R₂ are both phenyl, R₃ and R₄ are both ethyl,and R₅ and R₆ are both —H; R₁ and R₂ are both 4-cyanophenyl, R₃ and R₄are both methyl, R₅ is methyl, and R₆ is —H; R₁ and R₂ are both4-methoxyphenyl, R₃ and R₄ are both methyl, and R₅ and R₆ are both —H;R₁ and R₂ are both phenyl, R₃ and R₄ are both methyl, R₅ is methyl, andR₆ is —H; R₁ and R₂ are both phenyl, R₃ and R₄ are both ethyl, R₅ ismethyl, and R₆ is —H; R₁ and R₂ are both 4-cyanophenyl, R₃ and R₄ areboth methyl, and R₅ and R₆ are both —H; R₁ and R₂ are both2,5-dimethoxyphenyl, R₃ and R₄ are both methyl, and R₅ and R₆ are both—H; R₁ and R₂ are both 2,5-dimethoxyphenyl, R₃ and R₄ are both methyl,R₅ is methyl, and R₆ is —H; R₁ and R₂ are both ₃-cyanophenyl, R₃ and R₄are both methyl, and R₅ and R₆ are both —H; R₁ and R₂ are both₃-fluorophenyl, R₃ and R₄ are both methyl, and R₅ and R₆ are both —H; R₁and R₂ are both 4-chlorophenyl, R₃ and R₄ are both methyl, R₅ is methyl,and R₆ is —H; R₁ and R₂ are both 2-dimethoxyphenyl, R₃ and R₄ are bothmethyl, and R₅ and R₆ are both —H; R₁ and R₂ are both 3-methoxyphenyl,R₃ and R₄ are both methyl, and R₅ and R₆ are both —H; R₁ and R₂ are both2,3-dimethoxyphenyl, R₃ and R₄ are both methyl, and R₅ and R₆ are both—H; R₁ and R₂ are both 2,3-dimethoxyphenyl, R₃ and R₄ are both methyl,R₅ is methyl, and R₆ is —H; R₁ and R₂ are both 2,5-difluorophenyl, R₃and R₄ are both methyl, and R₅ and R₆ are both —H; R₁ and R₂ are both2,5-difluorophenyl, R₃ and R₄ are both methyl, R₅ is methyl, and R₆ is—H; R₁ and R₂ are both 2,5-dichlorophenyl, R₃ and R₄ are both methyl,and R₅ and R₆ are both —H; R₁ and R₂ are both 2,5-dimethylphenyl, R₃ andR₄ are both methyl, and R₅ and R₆ are both —H; R₁ and R₂ are both2,5-dimethoxyphenyl, R₃ and R₄ are both methyl, and R₅ and R₆ are both—H; R₁ and R₂ are both phenyl, R₃ and R₄ are both methyl, and R₅ and R₆are both —H; R₁ and R₂ are both 2,5-dimethoxyphenyl, R₃ and R₄ are bothmethyl, R₅ is methyl, and R₆ is —H; R₁ and R₂ are both cyclopropyl, R₃and R₄ are both methyl, and R₅ and R₆ are both —H; R₁ and R₂ are bothcyclopropyl, R₃ and R₄ are both ethyl, and R₅ and R₆ are both —H; R₁ andR₂ are both cyclopropyl, R₃ and R₄ are both methyl, R₅ is methyl, and R₆is —H; R₁ and R₂ are both 1-methylcyclopropyl, R₃ and R₄ are bothmethyl, and R₅ and R₆ are both —H; R₁ and R₂ are both1-methylcyclopropyl, R₃ and R₄ are both methyl, R₅ is methyl and R₆ is—H; R₁ and R₂ are both 1-methylcyclopropyl, R₃ and R₄ are both methyl,R₅ is ethyl, and R₆ is —H; R₁ and R₂ are both 1-methylcyclopropyl, R₃and R₄ are both methyl, R₅ is n-propyl, and R₆ is —H; R₁ and R₂ are both1-methylcyclopropyl, R₃ and R₄ are both methyl, and R₅ and R₆ are bothmethyl; R₁ and R₂ are both 1-methylcyclopropyl, R₃ and R₄ are bothethyl, and R₅ and R₆ are both —H; R₁ and R₂ are both1-methylcyclopropyl, R₃ is methyl, R₄ is ethyl, and R₅ and R₆ are both—H; R₁ and R₂ are both 2-methylcyclopropyl, R₃ and R₄ are both methyl,and R₅ and R₆ are both —H; R₁ and R₂ are both 2-phenylcyclopropyl, R₃and R₄ are both methyl, and R₅ and R₆ are both —H; R₁ and R₂ are both1-phenylcyclopropyl, R₃ and R₄ are both methyl, and R₅ and R₆ are both—H; R₁ and R₂ are both cyclobutyl, R₃ and R₄ are both methyl, and R₅ andR₆ are both —H; R₁ and R₂ are both cyclopentyl, R₃ and R₄ are bothmethyl, and R₅ and R₆ are both —H; R₁ and R₂ are both cyclohexyl, R₃ andR₄ are both methyl, and R₅ and R₆ are both —H; R₁ and R₂ are bothcyclohexyl, R₃ and R₄ are both phenyl, and R₅ and R₆ are both —H; R₁ andR₂ are both methyl, R₃ and R₄ are both methyl, and R₅ and R₆ are both—H; R₁ and R₂ are both methyl, R₃ and R₄ are both t-butyl, and R₅ and R₆are both —H; R₁ and R₂ are both methyl, R₃ and R₄ are both phenyl, andR₅ and R₆ are both —H; R₁ and R₂ are both t-butyl, R₃ and R₄ are bothmethyl, and R₅ and R₆ are both —H; R₁ and R₂ are ethyl, R₃ and R₄ areboth methyl, and R₅ and R₆ are both —H; or R₁ and R₂ are both n-propyl,R₃ and R₄ are both methyl, and R₅ and R₆ are both —H.

In specific embodiments, the bis(thiohydrazide amides) are representedby Structural Formula V:

wherein: R₁ and R₂ are both phenyl, and R₃ and R₄ are both o-CH₃-phenyl;R₁ and R₂ are both o-CH₃C(O)O-phenyl, and R₃ and R₄ are phenyl; R₁ andR₂ are both phenyl, and R₃ and R₄ are both methyl; R₁ and R₂ are bothphenyl, and R₃ and R₄ are both ethyl; R₁ and R₂ are both phenyl, and R₃and R₄ are both n-propyl; R₁ and R₂ are both p-cyanophenyl, and R₃ andR₄ are both methyl; R₁ and R₂ are both p-nitro phenyl, and R₃ and R₄ areboth methyl; R₁ and R₂ are both 2,5-dimethoxyphenyl, and R₃ and R₄ areboth methyl; R₁ and R₂ are both phenyl, and R₃ and R₄ are both n-butyl;R₁ and R₂ are both p-chlorophenyl, and R₃ and R₄ are both methyl; R₁ andR₂ are both 3-nitrophenyl, and R₃ and R₄ are both methyl; R₁ and R₂ areboth 3-cyanophenyl, and R₃ and R₄ are both methyl; R₁ and R₂ are both3-fluorophenyl, and R₃ and R₄ are both methyl; R₁ and R₂ are both2-furanyl, and R₃ and R₄ are both phenyl; R₁ and R₂ are both2-methoxyphenyl, and R₃ and R₄ are both methyl; R₁ and R₂ are both3-methoxyphenyl, and R₃ and R₄ are both methyl; R₁ and R₂ are both2,3-dimethoxyphenyl, and R₃ and R₄ are both methyl; R₁ and R₂ are both2-methoxy-5-chlorophenyl, and R₃ and R₄ are both ethyl; R₁ and R₂ areboth 2,5-difluorophenyl, and R₃ and R₄ are both methyl; R₁ and R₂ areboth 2,5-dichlorophenyl, and R₃ and R₄ are both methyl; R₁ and R₂ areboth 2,5-dimethylphenyl, and R₃ and R₄ are both methyl; R₁ and R₂ areboth 2-methoxy-5-chlorophenyl, and R₃ and R₄ are both methyl; R₁ and R₂are both 3,6-dimethoxyphenyl, and R₃ and R₄ are both methyl; R₁ and R₂are both phenyl, and R₃ and R₄ are both 2-ethylphenyl; R₁ and R₂ areboth 2-methyl-5-pyridyl, and R₃ and R₄ are both methyl; or R₁ is phenyl;R₂ is 2,5-dimethoxyphenyl, and R₃ and R₄ are both methyl; R₁ and R₂ areboth methyl, and R₃ and R₄ are both p-CF₃-phenyl; R₁ and R₂ are bothmethyl, and R₃ and R₄ are both o-CH₃-phenyl; R₁ and R₂ are both—(CH₂)₃COOH; and R₃ and R₄ are both phenyl; R₁ and R₂ are bothrepresented by the following structural formula

and R₃ and R₄ are both phenyl; R₁ and R₂ are both n-butyl, and R₃ and R₄are both phenyl; R₁ and R₂ are both n-pentyl, R₃ and R₄ are both phenyl;R₁ and R₂ are both methyl, and R₃ and R₄ are both 2-pyridyl; R₁ and R₂are both cyclohexyl, and R₃ and R₄ are both phenyl; R₁ and R₂ are bothmethyl, and R₃ and R₄ are both 2-ethylphenyl; R₁ and R₂ are both methyl,and R₃ and R₄ are both 2,6-dichlorophenyl; R₁-R₄ are all methyl; R₁ andR₂ are both methyl, and R₃ and R₄ are both t-butyl; R₁ and R₂ are bothethyl, and R₃ and R₄ are both methyl; R₁ and R₂ are both t-butyl, and R₃and R₄ are both methyl; R₁ and R₂ are both cyclopropyl, and R₃ and R₄are both methyl; R₁ and R₂ are both cyclopropyl, and R₃ and R₄ are bothethyl; R₁ and R₂ are both 1-methylcyclopropyl, and R₃ and R₄ are bothmethyl; R₁ and R₂ are both 2-methylcyclopropyl, and R₃ and R₄ are bothmethyl; R₁ and R₂ are both 1-phenylcyclopropyl, and R₃ and R₄ are bothmethyl; R₁ and R₂ are both 2-phenylcyclopropyl, and R₃ and R₄ are bothmethyl; R₁ and R₂ are both cyclobutyl, and R₃ and R₄ are both methyl; R₁and R₂ are both cyclopentyl, and R₃ and R₄ are both methyl; R₁ iscyclopropyl, R₂ is phenyl, and R₃ and R₄ are both methyl.

Preferred examples of bis(thiohydrazide amides) include Compounds(1)-(18) and pharmaceutically acceptable salts and solvates thereof:

Particular examples of bis(thiohydrazide amides) include Compounds (1),(17), and (18) and pharmaceutically acceptable salts and solvatesthereof.

The taxanes employed in the disclosed invention include Taxol™ andTaxol™ analogs. Taxol™ or “paclitaxel” is a well-known anti-cancer drugwhich can act by enhancing and stabilizing microtubule formation. Thus,the term “Taxol™ analog” is defined herein to mean a compound which hasthe basic Taxol™ skeleton and which stabilizes microtubule formation.Many analogs of Taxol™ are known, including Taxotere™, also referred toas “docetaxol”. Taxol™ and Taxotere™ have the respective structuralformulas:

The taxanes employed in the disclosed invention have the basic taxaneskeleton as a common structure feature shown below in Structural FormulaVI:

Double bonds have been omitted from the cyclohexane rings in the taxaneskeleton represented by Structural Formula VI. It is to be understoodthat the basic taxane skeleton can include zero or one double bond inone or both cyclohexane rings, as indicated in the Taxol™ analogs andStructural Formulas VII and VIII below. A number of atoms have also beenomitted from Structural Formula VI to indicate sites in which structuralvariation commonly occurs among Taxol™ analogs.

A wide variety of substituents can decorate the taxane skeleton withoutadversely affecting biological activity. Also, zero, one or both of thecyclohexane rings of a Taxol™ analog can have a double bond at theindicated positions. For example, substitution on the taxane skeletonwith simply an oxygen atom indicates that hydroxyl, acyl, alkoxy orother oxygen-bearing substituent is commonly found at the site. It is tobe understood that these and other substitutions on the taxane skeletoncan be made without losing the ability to enhance and stabilizemicrotubule formation. Thus, the term “Taxol™ analog” is defined hereinto mean a compound which has the basic Taxol™ skeleton and whichstabilizes microtubule formation. The term taxane is defined herein toinclude compounds such as Taxol™ and the “Taxol™ analogs” describedherein, or a pharmaceutically acceptable salt or solvate thereof.

Typically, the taxanes employed in the disclosed invention arerepresented by Structural Formula VII or VIII:

R₁₀ is an optionally substituted lower alkyl group, an optionallysubstituted phenyl group, —SR₁₉, —NHR₁₉ or —OR₁₉.

R₁₁ is an optionally substituted lower alkyl group, an optionallysubstituted aryl group.

R₁₂ is —H, —OH, lower alkyl, substituted lower alkyl, lower alkoxy,substituted lower alkoxy, —O—C(O)-(lower alkyl), —O—C(O)-(substitutedlower alkyl), —O—CH₂—O-(lower alkyl)-S—CH₂—O-(lower alkyl).

R₁₃ is —H, —CH₃, or, taken together with R₁₄, —CH₂—.

R₁₄ is —H, —OH, lower alkoxy, —O—C(O)-(lower alkyl), substituted loweralkoxy, —O—C(O)-(substituted lower alkyl), —O—CH₂—O—P(O)(OH)₂,—O—CH₂—O-(lower alkyl), —O—CH₂—S-(lower alkyl) or, taken together withR₂₀, a double bond.

R₁₅—H, lower acyl, lower alkyl, substituted lower alkyl, alkoxymethyl,alkthiomethyl, —OC(O)—O(lower alkyl), —OC(O)—O(substituted lower alkyl),—OC(O)—NH(lower alkyl) or —OC(O)—NH(substituted lower alkyl).

R₁₆ is phenyl or substituted phenyl.

R₁₇ is —H, lower acyl, substituted lower acyl, lower alkyl, substituted,lower alkyl, (lower alkoxy)methyl or (lower alkyl)thiomethyl.

R₁₈—H, —CH₃ or, taken together with R₁₇ and the carbon atoms to whichR₁₇ and

R₁₈ are bonded, a five or six membered a non-aromatic heterocyclic ring.

R₁₉ is an optionally substituted lower alkyl group, an optionallysubstituted phenyl group.

R₂₀ is —H or a halogen.

R₂₁ is —H, lower alkyl, substituted lower alkyl, lower acyl orsubstituted lower acyl.

Preferably, the variables in Structural Formulas VII and VIII aredefined as follows: R₁₀ is phenyl, tert-butoxy, —S—CH₂—CH—(CH₃)₂,—S—CH(CH₃)₃, —S—(CH₂)₃CH₃, —O—CH(CH₃)₃, —NH—CH(CH₃)₃, —CH═C(CH₃)₂ orpara-chlorophenyl; R_(u) is phenyl, (CH₃)₂CHCH₂—, -2-furanyl,cyclopropyl or para-toluoyl; R₁₂ is —H, —OH, CH₃CO— or—(CH₂)₂—N-morpholino; R₁₃ is methyl, or, R₁₃ and R₁₄, taken together,are —CH₂—;

R₁₄ is —H, —CH₂SCH₃ or —CH₂—O—P(O)(OH)₂; R₁₅ is CH₃CO—;

R₁₆ is phenyl; R₁₇—H, or, R₁₇ and R₁₈, taken together, are —O—CO—O—;

R₁₈ is —H; R₂₀ is —H or —F; and R₂₁ is —H, —C(O)—CHBr—(CH₂)₁₃—CH₃ or—C(O)—(CH₂)₁₄—CH₃; —C(O)—CH₂—CH(OH)—COOH,—C(O)—CH₂—O—C(O)—CH₂CH(NH₂)—CONH₂, —C(O)—CH₂—O—CH₂CH₂OCH₃ or—C(O)—O—C(O)—CH₂CH₃.

Specific examples of Taxol™ analogs include the following compounds:

A Taxol™ analog can also be bonded to or be pendent from apharmaceutically acceptable polymer, such as a polyacrylamide. Oneexample of a polymer of this type is Taxol™ analog 22, below, which hasthe structure of a polymer comprising a taxol analog group pendent fromthe polymer backbone. The polymer is a terpolymer of the three monomerunits shown. The term “Taxol™ analog”, as it is used herein, includessuch polymers.

A “straight chained hydrocarbyl group” is an alkylene group, i.e.,—(CH₂)_(y)—, with one, or more (preferably one) internal methylenegroups optionally replaced with a linkage group. y is a positive integer(e.g., between 1 and 10), preferably between 1 and 6 and more preferably1 or 2. A “linkage group” refers to a functional group which replaces amethylene in a straight chained hydrocarbyl. Examples of suitablelinkage groups include a ketone (—C(O)—), alkene, alkyne, phenylene,ether (—O—), thioether (—S—), or amine (—N(R^(a))—), wherein R^(a) isdefined below. A preferred linkage group is —C(R₅R₆)—, wherein R₅ and R₆are defined above. Suitable substituents for an alkylene group and ahydrocarbyl group are those which do not substantially interfere withthe anti-cancer activity of the bis(thiohydrazide) amides and taxanes.R₅ and R₆ are preferred substituents for an alkylene or hydrocarbylgroup represented by Y.

An aliphatic group is a straight chained, branched or cyclicnon-aromatic hydrocarbon which is completely saturated or which containsone or more units of unsaturation. Typically, a straight chained orbranched aliphatic group has from 1 to about 20 carbon atoms, preferablyfrom 1 to about 10, and a cyclic aliphatic group has from 3 to about 10carbon atoms, preferably from 3 to about 8. An aliphatic group ispreferably a straight chained or branched alkyl group, e.g., methyl,ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl,hexyl, pentyl or octyl, or a cycloalkyl group with 3 to about 8 carbonatoms. A C1-C20 straight chained or branched alkyl group or a C3-C8cyclic alkyl group is also referred to as a “lower alkyl” group.

The term “aromatic group” may be used interchangeably with “aryl,” “arylring,” “aromatic ring,” “aryl group” and “aromatic group.” Aromaticgroups include carbocyclic aromatic groups such as phenyl, naphthyl, andanthracyl, and heteroaryl groups such as imidazolyl, thienyl, furanyl,pyridyl, pyrimidyl, pyranyl, pyrazolyl, pyrroyl, pyrazinyl, thiazole,oxazolyl, and tetrazole. The term “heteroaryl group” may be usedinterchangeably with “heteroaryl,” “heteroaryl ring,” “heteroaromaticring” and “heteroaromatic group.” The term “heteroaryl,” as used herein,means a mono- or multi-cyclic aromatic heterocycle which comprise atleast one heteroatom such as nitrogen, sulfur and oxygen, but mayinclude 1, 2, 3 or 4 heteroatoms per ring. Aromatic groups also includefused polycyclic aromatic ring systems in which a carbocyclic aromaticring or heteroaryl ring is fused to one or more other heteroaryl rings.Examples include benzothienyl, benzofuranyl, indolyl, quinolinyl,benzothiazole, benzooxazole, benzimidazole, quinolinyl, isoquinolinyland isoindolyl.

The term “arylene” refers to an aryl group which is connected to theremainder of the molecule by two other bonds. By way of example, thestructure of a 1,4-phenylene group is shown below:

Substituents for an arylene group are as described below for an arylgroup.

Non-aromatic heterocyclic rings are non-aromatic rings which include oneor more heteroatoms such as nitrogen, oxygen or sulfur in the ring. Thering can be five, six, seven or eight-membered. Examples includetetrahydrofuranyl, tetrahydrothiophenyl, morpholino, thiomorpholino,pyrrolidinyl, piperazinyl, piperidinyl, and thiazolidinyl.

Suitable substituents on an aliphatic group (including an alkylenegroup), non-aromatic heterocyclic group, benzylic or aryl group(carbocyclic and heteroaryl) are those which do not substantiallyinterfere with the anti-cancer activity of the bis(thiohydrazide) amidesand taxanes. A substituent substantially interferes with anti-canceractivity when the anti-cancer activity is reduced by more than about 50%in a compound with the substituent compared with a compound without thesubstituent. Examples of suitable substituents include —R^(a), —OH, —Br,—Cl, —I, —F, —OR^(a), —O—COR^(a), —COR^(a), —CN, —NO₂, —COOH, —SO₃H,—NH₂, —NHR^(a), —N(R^(a)R^(b)), —COOR^(a), —CHO, —CONH₂, —CONHR^(a),—CON(R^(a)R^(b)), —NHCOR^(a), —NR^(c)COR^(a), —NHCONH₂, —NHCONR^(a)H,—NHCON(R^(a)R^(b)), —NR^(c)CONH₂, —NR^(c)CONR^(a)H,—NR^(c)CON(R^(a)R^(b)), —C(═NH)—NH₂, —C(═NH)—NHR^(a),—C(═NH)—N(R^(a)R^(b)), —C(═NR^(c))—NH₂, —C(═NR^(c))—NHR^(a),—C(═NR^(c))—N(R^(a)R^(b)), —NH—C(═NH)—NH₂, —NH—C(═NH)—NHR^(a),—NH—C(═NH)—N(R^(a)R^(b)), —NH—C(═NR^(c))—NH₂, —NH—C(═NR^(c))—NHR^(a),—NH—C(═NR^(c))—N(R^(a)R^(b)), —NR^(d)H—C(═NH)—NH₂,—NR^(d)—C(═NH)—NHR^(a), —NR^(d)—C(═NH)—N(R^(a)R^(b)),—NR^(d)—C(═NR^(c))—NH₂, —NR^(d)—C(═NR^(c))—NHR^(a),—NR^(d)—C(═NR^(c))—N(R^(a)R^(b)), —NHNH₂, —NHNHR^(a), —NHR^(a)R^(b),—SO₂NH₂, —SO₂NHR^(a), —SO₂NR^(a)R^(b), —CH═CHR^(a), —CH═CR^(a)R^(b),—CR^(c)═CR^(a)R^(b), —CR^(c)═CHR^(a), —CR^(c)═CR^(a)R^(b), —CCR^(a),—SH, —SR^(a), —S(O)R^(a), —S(O)₂R^(a). R^(a)—R^(d) are eachindependently an alkyl group, aromatic group, non-aromatic heterocyclicgroup or —N(R^(a)R^(b)), taken together, form an optionally substitutednon-aromatic heterocyclic group. The alkyl, aromatic and non-aromaticheterocyclic group represented by R^(a)—R^(d) and the non-aromaticheterocyclic group represented by —N(R^(a)R^(b)) are each optionally andindependently substituted with one or more groups represented by R^(#).

R^(#) is R⁺, —OR⁺, —O(haloalkyl), —SR⁺, —NO₂, —CN, —NCS, —N(R⁺)₂,—NHCO₂R⁺, —NHC(O)R⁺, —NHNHC(O)R⁺, —NHC(O)N(R⁺)₂, —NHNHC(O)N(R⁺)₂,—NHNHCO₂R⁺, —C(O)C(O)R⁺, —C(O)CH₂C(O)R⁺, —CO₂R⁺, —C(O)R⁺, —C(O)N(R⁺)₂,—OC(O)R⁺, —OC(O)N(R⁺)₂, —S(O)₂R⁺, —SO₂N(R⁺)₂, —S(O)R⁺, —NHSO₂N(R⁺)₂,—NHSO₂R⁺, —C(═S)N(R⁺)₂, or —C(═NH)—N(R⁺)₂.

R⁺ is —H, a C1-C4 alkyl group, a monocyclic heteroaryl group, anon-aromatic heterocyclic group or a phenyl group optionally substitutedwith alkyl, haloalkyl, alkoxy, haloalkoxy, halo, —CN, —NO₂, amine,alkylamine or dialkylamine. Optionally, the group —N(R⁺)₂ is anon-aromatic heterocyclic group, provided that non-aromatic heterocyclicgroups represented by R⁺ and —N(R⁺)₂ that comprise a secondary ringamine are optionally acylated or alkylated.

Preferred substituents for a phenyl group, including phenyl groupsrepresented by R₁-R₄, include C1-C4 alkyl, C1-C4 alkoxy, C1-C4haloalkyl, C1-C4 haloalkoxy, phenyl, benzyl, pyridyl, —OH, —NH₂, —F,—Cl, —Br, —I, —NO₂ or —CN.

Preferred substituents for an aliphatic group, including aliphaticgroups represented by R₁-R₄, include C1-C4 alkyl, C1-C4 alkoxy, C1-C4haloalkyl, C1-C4 haloalkoxy, phenyl, benzyl, pyridyl, —OH, —NH₂, —F,—Cl, —Br, —I, —NO₂ or —CN.

Preferred substituents for a cycloalkyl group, including cycloalkylgroups represented by R₁ and R₂, are alkyl groups, such as a methyl orethyl groups.

Also included in the present invention are pharmaceutically acceptablesalts of the bis(thiohydrazide) amides and taxanes employed herein.These compounds can have one or more sufficiently acidic protons thatcan react with a suitable organic or inorganic base to form a baseaddition salt. Base addition salts include those derived from inorganicbases, such as ammonium or alkali or alkaline earth metal hydroxides,carbonates, bicarbonates, and the like, and organic bases such asalkoxides, alkyl amides, alkyl and aryl amines, and the like. Such basesuseful in preparing the salts of this invention thus include sodiumhydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate,and the like.

For example, pharmaceutically acceptable salts of bis(thiohydrazide)amides and taxanes employed herein (e.g., those represented byStructural Formulas I-VI, Compounds 1-18, and Taxol™ analogs 1-22) arethose formed by the reaction of the compound with one equivalent of asuitable base to form a monovalent salt (i.e., the compound has singlenegative charge that is balanced by a pharmaceutically acceptablecounter cation, e.g., a monovalent cation) or with two equivalents of asuitable base to form a divalent salt (e.g., the compound has atwo-electron negative charge that is balanced by two pharmaceuticallyacceptable counter cations, e.g., two pharmaceutically acceptablemonovalent cations or a single pharmaceutically acceptable divalentcation). Divalent salts of the bis(thiohydrazide amides) are preferred.“Pharmaceutically acceptable” means that the cation is suitable foradministration to a subject. Examples include Li⁺, Na⁺, K⁺, Mg²⁺, Ca²⁺and NR₄ ⁺, wherein each R is independently hydrogen, an optionallysubstituted aliphatic group (e.g., a hydroxyalkyl group, aminoalkylgroup or ammoniumalkyl group) or optionally substituted aryl group, ortwo R groups, taken together, form an optionally substitutednon-aromatic heterocyclic ring optionally fused to an aromatic ring.Generally, the pharmaceutically acceptable cation is Li⁺, Na⁺, K⁺,NH₃(C₂H₅OH)⁺ or N(CH₃)₃(C₂H₅OH)⁺, and more typically, the salt is adisodium or dipotassium salt, preferably the disodium salt.

Bis(thiohydrazide) amides and taxanes employed herein having asufficiently basic group, such as an amine can react with an organic orinorganic acid to form an acid addition salt. Acids commonly employed toform acid addition salts from compounds with basic groups are inorganicacids such as hydrochloric acid, hydrobromic acid, hydroiodic acid,sulfuric acid, phosphoric acid, and the like, and organic acids such asp-toluenesulfonic acid, methanesulfonic acid, oxalic acid,p-bromophenyl-sulfonic acid, carbonic acid, succinic acid, citric acid,benzoic acid, acetic acid, and the like. Examples of such salts includethe sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate,monohydrogenphosphate, dihydrogenphosphate, metaphosphate,pyrophosphate, chloride, bromide, iodide, acetate, propionate,decanoate, caprylate, acrylate, formate, isobutyrate, caproate,heptanoate, propiolate, oxalate, malonate, succinate, suberate,sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate,benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate,hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate,phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate,gamma-hydroxybutyrate, glycolate, tartrate, methanesulfonate,propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate,mandelate, and the like.

Particular salts of the bis(thiohydrazide amide) compounds describedherein can be prepared according to methods described in copending,co-owned Patent Application Ser. No. 60/582,596, filed Jun. 23, 2004.

The neutral bis(thiohydrazide) amides can be prepared according tomethods described in U.S. Pat. Nos. 6,800,660, and 6,762,204, bothentitled “Synthesis of Taxol Enhancers” and also according to methodsdescribed in the co-pending and co-owned U.S. patent application Ser.Nos. 10/345,885 filed Jan. 15, 2003, and 10/758,589, Jan. 15, 2004. Theentire teachings of each document referred to in this application isexpressly incorporated herein by reference.

It will also be understood that certain compounds employed in theinvention may be obtained as different stereoisomers (e.g.,diastereomers and enantiomers) and that the invention includes allisomeric forms and racemic mixtures of the disclosed compounds andmethods of treating a subject with both pure isomers and mixturesthereof, including racemic mixtures. Stereoisomers can be separated andisolated using any suitable method, such as chromatography.

As used herein, a “subject” is a mammal, preferably a human, but canalso be an animal in need of veterinary treatment, e.g., companionanimals (e.g., dogs, cats, and the like), farm animals (e.g., cows,sheep, pigs, horses, and the like) and laboratory animals (e.g., rats,mice, guinea pigs, and the like).

The bis(thiohydrazide) amides and taxanes employed herein can beadministered to a subject by any conventional method of drugadministration for treatment of cancerous disorders, for example, orallyin capsules, suspensions or tablets or by parenteral administration.Parenteral administration can include, for example, systemicadministration, such as by intramuscular, intravenous, subcutaneous, orintraperitoneal injection. In specific embodiments, oral, parenteral, orlocal administration are preferred modes of administration for treatmentof cancer. Preferably, the mode of administration is intravenous.

An effective amount of a bis(thio-hydrazide) amide or a taxaneanticancer compound is a quantity in which anti-cancer effects arenormally achieved. With respect to a particular compound in the method(e.g., the bis(thio-hydrazide) amide or the taxane anticancer compound),an “effective amount” is the quantity in which a greater anti-cancereffect is achieved when the particular compound is co-administered withthe other compounds in the method compared with when the particularcompound is administered alone. The compounds of the method can beco-administered to the subject as part of the same pharmaceuticalcomposition or, alternatively, as separate pharmaceutical compositions.When administered as separate pharmaceutical compositions, the compoundsof the method can be administered simultaneously or at different times,provided that the enhancing effect of the compounds in combination isretained.

As used herein, “treating a subject with a cancer,” or similar terms,includes achieving, partially or substantially, one or more of thefollowing: arresting the growth or spread of a cancer, reducing theextent of a cancer (e.g., reducing size of a tumor or reducing thenumber of affected sites), inhibiting the growth rate of a cancer, andameliorating or improving a clinical symptom or indicator associatedwith a cancer (such as tissue or serum components).

In various embodiments, cancer can include human sarcomas andcarcinomas, e.g., fibrosarcoma, myxo sarcoma, liposarcoma,chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma,synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma,rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer,ovarian cancer, prostate cancer, squamous cell carcinoma, basal cellcarcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous glandcarcinoma, papillary carcinoma, papillary adenocarcinomas,cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renalcell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma,seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testiculartumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma,epithelial carcinoma, glioma, astrocytoma, medulloblastoma,craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acousticneuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma,retinoblastoma; leukemias, e.g., acute lymphocytic leukemia and acutemyelocytic leukemia (myeloblastic, promyelocytic, myelomonocytic,monocytic and erythroleukemia); chronic leukemia (chronic myelocytic(granulocytic) leukemia and chronic lymphocytic leukemia); andpolycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin'sdisease), multiple myeloma, Waldenstrobm's macroglobulinemia, and heavychain disease.

In some embodiments, cancer can include leukemias e.g., acute and/orchronic leukemias, e.g., lymphocytic leukemia (e.g., as exemplified bythe p388 (murine) cell line), large granular lymphocytic leukemia, andlymphoblastic leukemia; T-cell leukemias, e.g., T-cell leukemia (e.g.,as exemplified by the CEM, Jurkat, and HSB-2 (acute), YAC-1 (murine)cell lines), T-lymphocytic leukemia, and T-lymphoblastic leukemia; Bcell leukemia (e.g., as exemplified by the SB (acute) cell line), andB-lymphocytic leukemia; mixed cell leukemias, e.g., B and T cellleukemia and B and T lymphocytic leukemia; myeloid leukemias, e.g.,granulocytic leukemia, myelocytic leukemia (e.g., as exemplified by theHL-60 (promyelocyte) cell line), and myelogenous leukemia (e.g., asexemplified by the K562(chronic)cell line); neutrophilic leukemia;eosinophilic leukemia; monocytic leukemia (e.g., as exemplified by theTHP-1 (acute) cell line); myelomonocytic leukemia; Naegeli-type myeloidleukemia; and nonlymphocytic leukemia. Other examples of leukemias aredescribed in Chapter 60 of The Chemotherapy Sourcebook, Michael C. PerryEd., Williams & Williams (1992) and Section 36 of Holland Frie CancerMedicine 5th Ed., Bast et al. Eds., B.C. Decker Inc. (2000). The entireteachings of the preceding references are incorporated herein byreference.

In certain embodiments, cancer can include non-solid tumors such asmultiple myeloma, T-leukemia (e.g., as exemplified by Jurkat and CEMcell lines); B-leukemia (e.g., as exemplified by the SB cell line);promyelocytes (e.g., as exemplified by the HL-60 cell line); uterinesarcoma (e.g., as exemplified by the MES-SA cell line); monocyticleukemia (e.g., as exemplified by the THP-1 (acute) cell line); andlymphoma (e.g., as exemplified by the U937 cell line).

In some embodiments, cancer can include colon cancer, pancreatic cancer,melanoma, renal cancer, sarcoma, breast cancer, ovarian cancer, lungcancer, stomach cancer, bladder cancer and cervical cancer.

In some embodiments, the disclosed methods can be particularly effectiveat treating subjects whose cancer has become “multi-drug resistant”. Acancer which initially responded to an anti-cancer drug becomesresistant to the anti-cancer drug when the anti-cancer drug is no longereffective in treating the subject with the cancer. For example, manytumors can initially respond to treatment with an anti-cancer drug bydecreasing in size or even going into remission, only to developresistance to the drug. Drug resistant tumors are characterized by aresumption of their growth and/or reappearance after having seeminglygone into remission, despite the administration of increased dosages ofthe anti-cancer drug. Cancers that have developed resistance to two ormore anti-cancer drugs are said to be “multi-drug resistant”. Forexample, it is common for cancers to become resistant to three or moreanti-cancer agents, often five or more anti-cancer agents and at timesten or more anti-cancer agents.

The bis(thiohydrazide) amides and taxanes employed herein can beadministered to the subject in conjunction with an acceptablepharmaceutical carrier or diluent as part of a pharmaceuticalcomposition for treatment cancer therapy. Formulation of the compound tobe administered will vary according to the route of administrationselected (e.g., solution, emulsion, capsule, and the like). Suitablepharmaceutically acceptable carriers may contain inert ingredients whichdo not unduly inhibit the biological activity of the compounds. Thepharmaceutically acceptable carriers should be biocompatible, i.e.,non-toxic, non-inflammatory, non-immunogenic and devoid of otherundesired reactions upon the administration to a subject. Standardpharmaceutical formulation techniques can be employed, such as thosedescribed in Remington's Pharmaceutical Sciences, ibid. Suitablepharmaceutical carriers for parenteral administration include, forexample, sterile water, physiological saline, bacteriostatic saline(saline containing about 0.9% mg/ml benzyl alcohol), phosphate-bufferedsaline, Hank's solution, Ringer's-lactate and the like. Methods forencapsulating compositions (such as in a coating of hard gelatin orcyclodextran) are known in the art (Baker, et al., “Controlled Releaseof Biological Active Agents”, John Wiley and Sons, 1986).

In certain embodiments, one or more compounds of the invention and oneor more other the therapies (e.g., prophylactic or therapeutic agents)are cyclically administered. Cycling therapy involves the administrationof a first therapy (e.g., a first prophylactic or therapeutic agents)for a period of time, followed by the administration of a second therapy(e.g., a second prophylactic or therapeutic agents) for a period oftime, followed by the administration of a third therapy (e.g., a thirdprophylactic or therapeutic agents) for a period of time and so forth,and repeating this sequential administration, i.e., the cycle in orderto reduce the development of resistance to one of the agents, to avoidor reduce the side effects of one of the agents, and/or to improve theefficacy of the treatment.

In various embodiments, the methods herein can include administrationprior to or concurrently with the bis(thiohydrazide) amide/taxanecombination, agents that can reduce acute irritation or allergicreaction to administration, e.g., an anti-inflammatory such as Decadron®(dexamethasone, e.g., 10 mg intravenously), an antihistamine such asBenadryl® (diphenhydramine, e.g., 50 mg intravenously), an antacid suchas Zantac® (ranitidine hydrochloride, e.g., 50 mg intravenously), andthe like.

EXEMPLIFICATION Example 1 Measurement of Heat Shock Protein 70 (Hsp70)

Plasma Hsp70 was measured by a sandwich ELISA kit (Stressgen BioreagentsVictoria, British Columbia, CANADA) according to a modified protocol inhouse. In brief, Hsp70 in plasma specimens and serial concentrations ofHsp70 standard were captured onto 96-well plate on which anti-Hsp70antibody was coated. Then captured Hsp70 was detected with abiotinylated anti-Hsp70 antibody followed by incubation witheuropium-conjugated streptavidin. After each incubation unboundmaterials were removed by washing. Finally, antibody-Hsp70 complex wasmeasured by time resolved fluorometry of europium. Concentration ofHsp70 was calculated from a standard curve.

Example 2 Measurement of Natural Killer Cell Cytotoxic Activity

The following procedure can be employed to assay NK cell activity in asubject. The procedure is adapted from Kantakamalakul W, Jaroenpool J,Pattanapanyasat K. A novel enhanced green fluorescent protein(EGFP)-K562 flow cytometric method for measuring natural killer (NK)cell cytotoxic activity. J Immunol Methods. 2003 Jan. 15; 272:189-197,the entire teachings of which are incorporated herein by reference.

Materials and methods: Human erythroleukaemic cell line, K562, wasobtained from American Type Culture Collection (CCL-243, American TypeCulture Collection, Manassas, Va.), and cultured in RPMI-1640 medium(Cat#11875-093 Gibco Invitrogen Corp, Carlsbad, Calif.) supplementedwith 10% heat inactivated fetal calf serum (Gibco), 2 mM L-glutamin, 100μg/ml streptomycin and 100 IU/ml penicillin at 37° C. with 5% CO₂. K562cells were transduced with retroviral vector which encode greenfluorescent protein (eGFP). Stable cell line was selected withantibiotic, G418. About 99.6% G418 resistant cells were eGFP positiveafter section.

The subject's peripheral blood mononuclear cells (PBMCs) were preparedby clinical study sites and received in BD Vacutainer Cell PreparationTube with sodium heparin (Product Number: 362753, Becton Dickinson,Franklin Lakes, N.J.).

Two-fold serial dilution of 800 μl effector cells (patient's PBMC)starting at concentration of 1×10⁶ cells/mL were put into fourindividual polystyrene 12×75-mm tubes. Log phase growing target cells(K562/eGFP) were adjusted with growth medium (RPMI-1640) to aconcentration of 1×10⁵ cells/mL and 100 μL targets then added into thetubes to provide effector/target (E/T) ratios of 80:1, 40:1, 20:1, 10:1.Effector cells alone and target cells alone were used as controls. Alltubes were incubated at 37° C. with 5% CO₂ for about 3.5 hr. Tenmicroliters of propidium iodide (PI) at a concentration of 1 mg/mL wasadded to each tube including effector and target control tubes and thenincubated at room temperature for 15 min.

Cytotoxic activity was analyzed with a FACSCalibur flow cytometer(Becton Dickinson). Linear amplification of the forward and side scatter(FSC/SSC) signals, as well as logarithmic amplification of eGFP and PIemission in green and red fluorescence were obtained. Ten thousandevents per sample tube with no gating for acquisition were collected foranalysis. Data analysis for two-parameter dot plots for eGFP versus PIwas performed using CELLQuest (Becton Dickinson Biosciences) software toenumerate live and dead target cells. Debris and dead cells wereexcluded by setting a threshold of forward light scatter.

Example 3 The Disclosed Combination Therapy Induces Hsp70

A Phase I trial was conducted for combined administration of abis(thio-hydrazide) amide (Compound (1)) and a taxane (paclitaxel) tohuman subjects with various advanced solid tumors. Compound (1) andpaclitaxel were co-administered intravenously over 3 hours every 3weeks. Starting doses were 44 milligrams/meter² (mg/m2, or 110micromoles/meter² (μmol/m2)) Compound (1) and 135 mg/m2 (158 μmol/m2)paclitaxel. Paclitaxel was then increased to 175 mg/m2 (205 μmol/m2),followed by escalation of Compound (1) to establish the maximumtolerated dose based on first cycle toxicity in 3 to 6 patients at eachdose level. Pharmacokinetic (PK) studies were performed during cycle 1using liquid chromatography/mass spectrometry (LC/MS) to measure bothcompounds in plasma. Heat shock protein 70 (Hsp70) was measured inplasma before and after treatment. 35 patients were evaluated at 8 doselevels, including paclitaxel at 135 mg/m2 (158 μmol/m2) and Compound (1)at 44 mg/m2, and paclitaxel at 175 mg/m2 (205 μmol/m2) and Compound (1)at a doses ranging among 44-525 mg/m2 (110-1311 μmol/m2). Table 1 showsthe eight different doses #1-#8 in mg/m² and μmol/m².

TABLE 1 #1 #2 #3 #4 #5 #6 #7 #8 Compound (1), 44 44 88 175 263 350 438525 mg/m² Compound (1), 110 110 220 437 657 874 1094 1311 μmol/m²Paclitaxel, 135 175 175 175 175 175 175 175 mg/m² Paclitaxel, 158 205205 205 205 205 205 205 μmol/m²

No serious effects specifically attributable to Compound (1) wereobserved. Paclitaxel dose limiting toxicities occurred in a singlepatient in each of the top three dose levels (neutropenia, arthralgia,and febrile neutropenia with mucositis) resulting in cohort expansion.Compound (1) exhibited linear PK that was unaffected by paclitaxel dose,and was rapidly eliminated from plasma with terminal-phase half life of0.94±0.23 hours (h) and total body clearance of 28±8 Liters/hour/meter²(L/h/m²). Its apparent volume of distribution was comparable to totalbody water (V_(SS)23±16 L/m²). Paclitaxel PK appeared to be moderatelydependent on the Compound (1) dose, as indicated by a significant trendtoward decreasing clearance, and increase in peak plasma concentrationand V_(SS), but without affecting the terminal phase half-life. Theseobservations are consistent with competitive inhibition of paclitaxelhepatic metabolism. Increased toxicity at higher dose levels wasconsistent with a moderate increase in systemic exposure to paclitaxel.Induction of Hsp70 protein in plasma was dose dependent, peaking betweenabout 8 hours to about 24 hours after dosing.

FIGS. 1A, 1B, and 1C are bar graphs showing the percent increase inHsp70 plasma levels associated with administration of the Compound(1)/paclitaxel combination therapy at 1 hour (FIG. 1A), 5 hours (FIG.1B), and 8 hours (FIG. 1C) after administration. Significant rises inHsp70 levels occurred for at least one patient at the 88 mg/m2 (220μmol/m2) Compound (1) dose, where Hsp70 levels nearly doubled in apercent increase of about 90%. At the 175 mg/m2 (437 μmol/m2) Compound(1) dose, Hsp70 concentrations more than doubled in two patients; at the263 mg/m2 (657 μmol/m2) Compound (1) dose, Hsp70 concentrations roughlydoubled in two patients and increased by more than 250% in a thirdpatient; at the 350 mg/m2 (874 μmol/m2) Compound (1) dose, Hsp70concentrations increased more than 200% in all patients and increased byas much as 500% in two patients; at the 438 mg/m2 (1094 μmol/m2)Compound (1) dose, Hsp70 concentrations roughly doubled in two patients,increased by over 2005 in one patient, and increased by as much as 500%in another patient.

Time to progression will be measured as the time from patientrandomization to the time the patient is first recorded as having tumorprogression according to the RECIST (Response Evaluation Criteria inSolid Tumors Group) criteria; see Therasse P, Arbuck S G, Eisenhauer EA, Wanders J, Kaplan R S, Rubinstein L, et al. New guidelines toevaluate the response to treatment in solid tumors. J Natl Cancer Inst2000; 92:205-16, the entire teachings of which are incorporated byreference. Death from any cause will be considered as progressed.

Time to progression can be performed on the randomized sample as well asthe efficacy sample. Treatment groups can be compared using the log-ranktest and Kaplan-Meier curves of time to progression can be presented.

Thus, the combination of a bi(thio-hydrazide) amide and taxanedramatically increased plasma Hsp70 levels in patients, givingsignificant increases for patients at a combined paclitaxel dose of 175mg/m2 (205 μmol/m2) and Compound (1) doses ranging from 88 through 438mg/m2 (220-1094 μmol/m2). Moreover, the combination was well-tolerated,with adverse events consistent with those expected for paclitaxel alone.

Example 4 A 2 Stage Phase 2 Study Shows the Disclosed CombinationTherapy is Effective for Treating Advanced Metastatic Melanoma

The following study of Compound (1) and paclitaxel in patients withadvanced metastatic melanoma was initiated based on the biologicalactivity shown by the results of the above Phase I study, where thecombined administration Compound (1) and paclitaxel led to dose-relatedHsp70 induction.

The study included a Stage 1 initial safety assessment of the weeklydose schedule, where Compound (1) 106 mg/m2 (265 μmol/m2) and paclitaxelat 80 mg/m2 (94 μmol/m2) were administered weekly for 3 weeks out a 4week period. The dose of Compound (1) was then escalated to 213 mg/m2(532 μmol/m2) in combination with the paclitaxel at 80 mg/m2 (94μmol/m2). The higher tolerated dose level was expanded to a total of 20patients (Stage 1).

A total of 7 patients were treated in the initial safety assessment, 3at the lower dose level and 4 at the higher. In the absence ofdose-limiting toxicities in either group, the higher dose level waschosen as the dose of interest and additional patients were enrolled tocomplete stage 1. Adverse events seen were as expected for paclitaxelchemotherapy administration. Of 20 evaluable patients, 11 were stable at3 months for 55% NPR.

The study will continue to Stage 2 if 7 or more patients have a responseof stable disease or better, or at least 2 patients have a partialresponse or better. A safety assessment was performed with the first 6patients enrolled a s the weekly dose schedule had not previously beenstudied in humans. The primary endpoint is non-progression rate (NPR) at3 months and response rate. Pharmacodynamic parameters include pre andpost-dose NK cell activity in blood and when possible, tumor biopsies.

Table 2 shows the significant preliminary results of anticancer efficacyand NK cell activity results when assayed 7 days after the second dosefor different subjects. The Effector/Target data shows the ratio of thesubjects PBMC cells to the NK assay target cells. The pre and post dosecolumn values show the percent of tumor cells lysed before dosing withPaclitaxel and Compound (1). Best Response indicates an evaluation ofthe patient's tumor: SD indicates less than 20% of an increase and lessthan 30% of a decrease in the sum of the longest diameters as comparedto baseline; and PD=at least a 20% increase in the sum of the longestdiameters as compared to baseline. NK Activity indicates the change inNK activity before and after dosing.

Table 2 shows that for patients completing the study (#12-#20, #22),three patients had less than 20% of an increase and less than 30% of adecrease in the sum of the longest diameters as compared to baseline,while seven patients had at least a 20% increase in the sum of thelongest diameters as compared to baseline. For NK cell activity, four ofthe original patients showed a statistically significant increasebetween pre- and post-dose treatment.

TABLE 2 % tumor dosing information Effec- cell lysis Cmpnd Best ResponseSub- tor/ pre- post- Paclitaxel, (1) cycle 2 NK ject Target dose dosemg/M² mg/M² week 4 activity 12 80:1 2.32 7.74 80 106 SD increase 13 80:16.13 2.43 80 106 PD decrease 14 80:1 3.83 10.77 80 213 SD increase 15(40:1) 3.5 10.01 80 213 PD (increase) 16 80:1 19.71 19.78 80 213 SD nochange 17 80:1 41.61 26.52 80 213 PD decrease 18 80:1 8.6 8.64 80 213 PDno change 19 80:1 24.76 18.77 80 213 PD decrease 20 80:1 16.49 5.2 80213 PD decrease 21 80:1 15.4 26.31 80 213 NA increase 22 80:1 10.81 7.280 213 PD decrease

The combination therapy was well-tolerated on the weekly schedule.Enrollment in the randomized portion will assess the activity ofCompound (1) in combination with paclitaxel versus paclitaxel alone.

Stage 2 is planned to be a randomized 2-arm study comparing the drugcombination to paclitaxel alone. The criterion for continuation to Stage2 is >=50% non-progression rate (NPR) at two months. A total of 78patients are to be randomized 2:1 (combination:control). The primaryendpoint is time to progression; secondary endpoints are response rate,survival, and quality of life. Pharmacodynamic parameters will includepre- and post-dose measurements of NK cell activity in blood and, whenpossible, tumor biopsies.

Example 5 A Phase 2 Study Shows the Disclosed Combination Therapy isEffective for Treating Soft Tissue Sarcomas

The following study of Compound (1) and paclitaxel in patients with softtissue sarcomas was initiated based on the biological activity shown bythe results of the above Phase I study, where the combinedadministration Compound (1) and paclitaxel led to dose-related Hsp70induction.

The study is a 2 stage design, enrolling 30 patients in the first stageand adding 50 patients to total 80 if certain continuation criteria aremet. Major inclusion criteria are refractory or recurrent soft tissuesarcomas other than gastrointestinal stromal tumor (GIST), with evidenceof recent progression. Patients are treated weekly, 3 weeks out of every4 week cycle with 213 mg/m2 Compound (1) and 80 mg/m2 paclitaxel. Forexample, the compounds were administered together 3 weeks out of 4 onDays 1, 8, and 15 of a 28 day cycle as a 1 hour IV infusion. 30 Patientshave been enrolled to completed accrual of Stage 1.

As used herein, “soft-tissue sarcomas” (STS) are cancers that begin inthe soft tissues that support, connect, and surround various parts ofthe body for example, soft tissues such as muscles, fat, tendons,nerves, and blood vessels, lymph nodes, or the like. Such STSs can occuranywhere in the body, though typically about one half occur in thelimbs. In various embodiments, STSs can include one or more cancersselected from liposarcoma, fibrosarcoma, malignant fibrous histiocytomaleiomyosarcoma, neurofibrosarcoma, rhabdomyosarcoma, synovial sarcoma,or the like.

Table 3 shows the significant preliminary results of anticancer efficacyand NK cell activity results when assayed 7 days after the second dosefor different subjects. The Effector/Target data shows the ratio of thesubjects PBMC cells to the NK assay target cells. The pre and post dosecolumn values show the percent of tumor cells lysed before dosing withPaclitaxel and Compound (1). Best Response indicates an evaluation ofthe patient's tumor: PR=at least a 30% decrease in the sum of thelongest diameters as compared to baseline; SD indicates less than 20% ofan increase and less than 30% of a decrease in the sum of the longestdiameters as compared to baseline; and PD=at least a 20% increase in thesum of the longest diameters as compared to baseline. NK Activityindicates the change in NK activity before and after dosing.

Table 3 shows that for patients completing the study (#23-#29, #31-33),five patients had less than 20% of an increase and less than 30% of adecrease in the sum of the longest diameters as compared to baseline,while five patients had at least a 20% increase in the sum of thelongest diameters as compared to baseline. For NK cell activity, sevenof the original patients showed a statistically significant increase orno change between pre- and post-dose treatment, while only four of theoriginal patients showed a decrease statistically significant increasebetween pre- and post-dose treatment.

TABLE 3 % tumor cell dosing information Effec- lysis Cmpnd Best ResponseSub- tor/ pre- post- Paclitaxel, (1) NK ject Target dose dose mg/M²mg/M² cycle 2 activity 23 80:1 4.28 30.48 80 213 PD increase 24 80:120.74 20.04 80 213 SD no change 25 80:1 34.28 11.86 80 213 PD decrease26 80:1 22.33 14.74 80 213 SD decrease 27 80:1 10.6 22.9 80 213 SDincrease 28 80:1 17.93 28.13 80 213 SD increase 29 80:1 6.58 17.18 80213 PD increase 30 (40:1) 9.88 9.91 80 213 NA no change 31 80:1 2.625.46 80 213 SD increase 32 80:1 13.03 7.41 80 213 PD decrease 33 80:115.77 7.84 80 213 PD decrease

Patients are currently being evaluated through 3 months. Adverse eventsseen were typical for paclitaxel administration on a similar schedule.Assessment of NK activity is ongoing. The addition of Compound (1) tothe weekly paclitaxel schedule was well-tolerated. Stage 1 accrual hascompleted, and patients are currently being evaluated for the studycontinuation decision.

While this invention has been particularly shown and described withreferences to preferred embodiments thereof, it will be understood bythose skilled in the art that various changes in form and details may bemade therein without departing from the scope of the inventionencompassed by the appended claims.

1. A method of treating a human with ovarian cancer comprising the stepof co-administering to the human over three to five weeks: paclitaxel ora paclitaxel analogue in an amount of between about 243 μmol/m² to 315μmol/m²; and a bis(thiohydrazide amide) in an amount between about 1473μmol/m² and about 1722 μmol/m², wherein the bis(thiohydrazide amide) isrepresented by the following Structural Formula:

or a pharmaceutically acceptable salt thereof.
 2. The method of claim 1,wherein the bis(thiohydrazide amide) is administered in combination withpaclitaxel or docetaxel.
 3. The method of claim 2, wherein thebis(thiohydrazide amide) is administered in combination with paclitaxel.4. The method of claim 3, wherein the paclitaxel and thebis(thiohydrazide amide) are each administered in three equal weeklydoses of three weeks of a four week period.
 5. The method of claim 4,further comprising repeating the four week administration period untilthe cancer is in remission.
 6. The method of claim 5, wherein thepaclitaxel is intravenously administered in a weekly dose of about 94μmol/m².
 7. The method of claim 6, wherein the bis(thiohydrazide amide)is intravenously administered in a weekly dose of between about 500μmol/m² and about 562 μmol/m².
 8. The method of claim 7, wherein thebis(thiohydrazide amide) is intravenously administered in a weekly doseof 532 μmol/m².
 9. The method of claim 1, wherein the bis(thiohydrazideamide) is the disodium or dipotassium salt.
 10. A method of treating ahuman with cancer, comprising intravenously administering to the humanin a four week period, three equal weekly doses of the paclitaxel in anamount of about 94 μmol/m² and a bis(thiohydrazide amide) represented bythe following Structural Formula:

or a pharmaceutically acceptable salt thereof in an amout of about 532μmol/m², wherein the cancer is ovarian cancer.